Scientific Publications

Advancing dermatological science.

April 2022

AMCP 2022

Effects of Roflumilast Cream on Patient Burden and Work Productivity in Patients With Psoriasis

April 2022

AAD 2022

Pooled Efficacy and Safety Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% by Baseline Body Surface Area

April 2022

AAD 2022

Pooled Efficacy and Safety Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% for Treatment of Chronic Plaque Psoriasis

April 2022

AAD 2022

Efficacy and Safety of Once-Daily Roflumilast Cream 0.3% in Patients With Knee/Elbow Involvement: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)

April 2022

AAD 2022

Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Interim Results From a 24-Week, Phase 3 Open-Label Study

April 2022

AAD 2022

Effect of Roflumilast Foam 0.3% Treatment of Seborrheic Dermatitis on Patient Quality of Life: Results From a Phase 2 Study

September 2021

EADV 2021

Roflumilast Cream 0.3%, Safety and Efficacy in Patients with Chronic Plaque Psoriasis (DERMIS-1 and DERMIS-2)

September 2021

EADV 2021

Roflumilast Foam 0.3% Improved the Severity and Burden of Itch in Patients with Scalp and Body Psoriasis

September 2021

EADV 2021

Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients with Chronic Plaque Psoriasis (DERMIS-1 and DERMIS-2)

September 2021

EADV 2021

Roflumilast Foam 0.3%, Safety and Efficacy in Patients with Seborrheic Dermatitis

July 2021

Dermatology and Therapy

Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score

May 2021

EADV Spring Symposium 2021

Roflumilast Cream, Safety and Efficacy in two Ph3 Studies (DERMIS-1 and DERMIS-2) in Patients with Chronic Plaque Psoriasis

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download